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Abstract
Objective Hyperplastic polyposis is a colonic polyposis
condition of unknown aetiology. The purpose of this study
wasto examine the spectrum of phenotypic variation in patients
with multiple serrated polyps as a basis for gene discovery.
Methods One hundred and twenty-six patients with multiple
(≥5)serratedpolypswererecruited tothestudy.Polypcounts
were extracted from histology and colonoscopy reports.
Ethnicity was self-reported. Family history of cancer data
were derived from pedigrees. Ascertainment status was
classified as either index case or identified by screening.
Results The average reported polyp count was 39. Patients
with highest polyp numbers were more likely to be male
(P=0.02). Colorectal cancer (CRC) was identified in 49 of
119 patients (41%) and 28% of these patients had multiple
CRC. Young onset patients had higher polyp numbers (P=
0.03) and were more likely to have their CRC in the distal
colon (P=0.02). CRC was significantly associated with the
presence of adenomas (P=0.03). Patients were divided into
moderate polyposis (5-79 serrated polyps) and dense
polyposis (80 or more) categories. The dense polyposis
category was associated with a lack of family history for
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DOI 10.1007/s00384-010-0907-8CRC (P=0.034) and male gender (P=0.014), independent
of ascertainment status and recruitment site.
Conclusion Multiple serrated polyps were associated with
an increased personal risk of CRC. A subset of patients
with the highest polyp numbers was more likely to be male
and to have no family history of CRC. This result suggests
heterogeneous modes of inheritance and has implications
for studies investigating the genetic basis of multiple
serrated polyps.
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Introduction
The recognition of the serrated neoplasia pathway has
facilitated investigation of the aetiology of the remaining
unexplained portion of familial colorectal cancer (CRC) [1,
2]. Analogous to the multiple adenoma syndromes familial
adenomatous polyposis and MUTYH-associated polyposis,
individuals with hyperplastic polyposis syndrome (HPS)
also develop CRC on a background of multiple polyps
throughout the colon but in contrast, most of the polyps in
HPS demonstrate serrated morphology. HPS was first
described in 1977 by Spjut and Estrada [3], frequently
presents with features consistent with a genetic predisposi-
tion to CRC [4], and is currently defined by the World
Health Organization (WHO) criteria as
1) at least five histologically diagnosed hyperplastic
polyps proximal to the sigmoid colon, two of which
are greater than 10 mm in diameter OR
2) any number of hyperplastic polyps occurring proximal
to the sigmoid colon in an individual who has a first-
degree relative with hyperplastic polyposis OR
3) more than 30 hyperplastic polyps of any size but
distributed throughout the colon [5].
The WHO criteria were originally introduced to distin-
guish HPS from the common observation of satellite
hyperplastic polyps around rectal cancers and diminutive
distal colon lesions, and to highlight observations that even
small numbers of larger hyperplastic polyps in the proximal
colon may be associated with increased malignant potential
[6]. However, because such definitions are necessarily
stringent and somewhat arbitrary, many individuals and
families with multiple hyperplastic polyps will fall short of
these criteria [7]. Since the publication of the criteria in
2000, several investigators have proposed modifications to
address these limitations. Higuchi and Jass have suggested
that atypical serrated polyps (these include sessile serrated
adenomas, serrated adenomas and mixed polyps) be includ-
ed in the total polyp count which can be cumulative over
time [8]. Variations on the threshold polyp count have been
proposed, with Chow et al. [9], Rashid et al. [10], Hyman et
al. [11], and Boparai et al. [12], all favouring a count of 20
hyperplastic polyps, and Carvajal-Carmona [13] using ten,
instead of a count of 30 as described by the criteria.
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704 Int J Colorectal Dis (2010) 25:703–712As reflected in the WHO criteria, HPS presents with
extensive phenotypic heterogeneity not only with respect to
the number and size of polyps, but also with regard to
presence of CRC, polyp histology, sex ratios, age of onset,
and the presence of a family history of CRC [10, 14–22]
(Table 1). The underlying basis for the observed phenotypic
heterogeneity is currently unclear; however, an analysis of
phenotype in a large series of high-risk patients with
multiple serrated polyps may contribute to our understand-
ing of this heterogeneity by identifying patterns of
inheritance and relationships between clinical features. In
this, the largest such patient group studied to date, we
examined the spectrum of presentations as an initial step to
establishing a modern classification for this condition upon
which to base gene discovery programmes, a procedure
best carried out in a high-risk population.
Patients and methods
The use of the term serrated polyp in this report encom-
passes any polyp with serrated architecture [23], and
includes both common (hyperplastic or metaplastic) and
advanced (serrated adenoma, sessile serrated adenoma, and
mixed polyp) lesions. Due to the limitations of the WHO
criteria, this cross-sectional study comprised 126 patients
with multiple serrated polyps (five or more) recruited from
genetics clinics in Australasia (n=94) and North America
(n=32) regardless of family history of polyps and cancer.
Using this approach which targets high-risk patients, we are
unlikely to have recruited elderly patients with common
distal serrated polyps, whilst at the same time recruiting
patients with clinically significant disease who may have
fallen short of the current WHO criteria. Thirty-eight
patients from Australasia and ten from North America have
been reported previously [9, 24]. Clinical and pathology
data were extracted from histology reports, minimum polyp
counts were derived from serial colonoscopy reports, where
available, accounting for polyps removed at each proce-
dure. Patients with polyps demonstrating hamartomatous
features were not included in the study. Smoking status was
recorded as never/ever and note was made of whether the
participants were currently smoking. Patients gave written
informed consent to participate in the research. The study
was approved by the Human Research Ethics Committee
(HREC) of Queensland Institute of Medical Research under
the Genetics of Serrated Neoplasia project (QIMR HREC
ProtocolP912).Self-reportedpaternal andmaternalethnicity
was recorded where available. Colorectal cancers were
verified in first-degree relatives (parents, children, and
siblings of the proband) using histology reports. Where
more than one instance of multiple serrated polyps was
present in a family, family history used the youngest proband
as a point of reference (n=6). In 118 families, we were
Table 1 Published series of HPS cases where n was greater than five individuals, highlighting the phenotypic diversity of HPS
Author Year Cases
HPS (n)
Mean age at
diagnosis (years)
Males
(%)
Number of polyps
observed
CRC
(%)
CRC in proximal
colon (%)
Family
history
of CRC
(%)
Buchanan
a 2009 126 49 50 5-150 40 59 59
Boparai [12] 2009 77 56 NS 2-53 35 NS NS
Chow [9] 2006 38 44 55 Multiple 26 40 50
Carvajal-
Carmona [13]
2007 32 46 66 multiple 25 NS 59
Renaut [19] 2001 28 58 54 Multiple 29 NS 39
Yeoman [40] 2007 24 61 42 Multiple 54 84 17
Ferrandez [15] 2004 15 53 66 Multiple 0 NS 0
Lage [16] 2004 14 58 NS 19-100 43 67 33
Hyman [11] 2004 13 62 38 Multiple 54 71 38
Rashid [10] 2000 13 58 54 Multiple 77 NS 38
Leggett [17] 2001 12 57 42 30 to >100 58 NS 17
Rubio [20] 2006 10 61 80 6-159 70 43 10
Spjut [3] 1977 9 53 NS Multiple 11 NS NS
Williams [21] 1980 7 37 86 50-150 0 NS 14
Torlakovic [30] 1996 6 57 83 50-100 67 NS NS
Place [18] 1999 6 60 100 50-100 50 100 14
NS not specified; multiple upper limit of polyp numbers not specified
aCurrent manuscript data
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presenting family member n=89) or screening cases (where
multiple serrated polyps were identified as a result of
screening due to family history of colonic neoplasia, n=32).
All but two index cases presented due to abdominal
symptoms (bleeding, pain, or change in habit). The
remaining two cases were diagnosed as an incidental
finding during investigations for a hernia repair and an
incidental finding at population screening due to age,
respectively. Polyp counts in the entire study group, as
well as in index cases showed a bimodal distribution and
fell into two groups (Fig. 1) about a cut-point polyp
count of 80, and were classified as either moderate poly-
posis (<80 polyps) or dense polyposis (≥80 polyps). All
screening cases were observed to be in the moderate
polyposis group.
Statistical analysis
The associations between categorical predictor variables were
assessed for statistical significance using an exact chi-squared
test and odds ratios where appropriate. Comparison of means
forageandminimumpolypcountdataweremadeusingt tests.
Missing data were excluded from the analysis. Multivariate
analysis was used for estimating the odds ratios and 95%
confidence intervals for the association between variables and
two categorical outcomes of polyp number (moderate versus
dense polyp count). All P values were two-sided and a P
value <0.05 was considered as statistically significant. SPSS
version 17 was used for all statistical analysis. In order to
limit the effects of ascertainment bias, any significant findings
were re-analysed in the subset of index cases.
Results
Characteristics of multiple serrated polyp patients
Table 2 shows that approximately one-half of patients were
female (one patient unreported gender), and almost all were
of Northern European ancestry, predominantly English,
Irish, Scots, Welsh, French or French-Canadian, German,
Swedish and Dutch. Six patients (5%) reported Italian,
Greek or Middle-eastern ancestry (two of each). Two
patients reported Anglo-Maori and Anglo-Middle-eastern
ethnicity, respectively, and a third patient had a Jamaican
parent. Two patients from a single family reported
European-Russian-Jewish ancestry.
Patients from North America did not differ significantly
from patients from Australia with respect to rates of CRC.
CRC was diagnosed in 41% of patients, the majority of
which were proximal (CRC site could not be confirmed in
eight patients). Nine of the 24 patients (38%) with a
proximal CRC had multiple (two to four) CRCs in the
proximal colon and all but one of these were synchronous
(Table 3). Multiple proximal CRCs were divided equally
between males and females. No multiple CRCs were seen
within in the distal colon; however, a further two patients
had both a proximal and a distal CRC. Overall, 11 of 40
patients had multiple CRC (28%). Females with CRC were
more likely to present with proximal malignancy than with
distal CRC, whilst males with CRC were evenly divided
between sites.
There was no significant difference in mean age at
presentation between the sexes (P=0.98), or between
patients with and without CRC (P=0.91), however, patients
presenting with CRC before age 50 were significantly more
Fig. 1 Frequency of polyp
count numbers showing the dis-
tribution of polyp counts in a
bimodal pattern about a polyp
count of 80 and a concentration
of screening cases below this
number
706 Int J Colorectal Dis (2010) 25:703–712likely to have a distal cancer than were patients who
presented with a CRC at 50 years or older (60% vs. 22%;
P=0.022), and patients presenting before age 50 had
significantly more polyps (45 vs. 34; P=0.03). Approxi-
mately three-quarters of patients had a first- or second-
degree relative with CRC. Fifty-nine percent of the patients
had a first-degree relative with CRC (60% of females and
59% of males; P=0.90). Fifty-eight percent of participants
had smoked for more than 3 months, and 24% of the
participants were currently smoking. There was no differ-
ence between the sexes for current smoking status, with
22% of males and 30% of females continuing to smoke.
Many patients (85%) had at least one polyp clearly
reported as an adenoma, and CRC was significantly
associated with the presence of these lesions (P=0.03).
Specialist pathology review was carried out by two
gastrointestinal pathologists (JRJ and NIW) and serrated
polyp sub-classification (common vs. advanced serrated
polyps) was available on 70 patients. Approximately two-
thirds had at least one advanced serrated polyp, and this
proportion did not differ between patients with and
without CRC. Though advanced serrated polyps were
more likely to arise in females and those presenting at
50 years or older, the differences did not attain statistical
significance.
Number of serrated polyps
The mean reported number of hyperplastic polyps per
patient was 39 (Table 2). We found no difference in mean
reported polyp number by sex, CRC, between patients with
and without advanced serrated polyps, (Table 3) or between
patients from Australia and North America. Mean reported
polyp count was 40% lower in patients with a first-degree
relative with CRC (32, 95% CI 26-39) compared to patients
without a first-degree relative with CRC (53, 95% CI 41-
64; P=0.008). Moreover, there was also a significant
difference in the mean reported polyp count between the
patients with any first- or second-degree relative with CRC
(36, 95% CI 29-44) and without any relative with CRC (58,
95% CI 43-73; P=0.003). Current smokers had a higher
reported polyp count (51 vs. 34; P=0.043).
Ascertainment issues
Where information could be obtained, index cases com-
prised 89/122 multiple serrated polyp patients (73%) and
the characteristics of these patients and those identified due
to screening (n=32, 27%) are shown in Table 4. When
gender and family history of CRC were analysed in the first
presenting patient in a family, mean reported polyp count
was significantly lower in females (39 vs. 48; P=0.047)
and in patients with a first-degree relative with CRC (34 vs.
55; P=0.026) though in both cases, the variance was large.
Consistent with these findings, the mean reported polyp
count in individuals screened because of family history was
low, as was the rate of CRC in these asymptomatic patients.
In three screening cases, patients were examined due to
non-malignant colonic neoplasia in a relative, and all of
these had relatively high polyp counts.
In 47 families, Lynch syndrome could be excluded by
immunohistochemistry for mismatch repair genes coupled
with BRAF mutation testing. In two families, both Lynch
syndrome and multiple serrated neoplasms segregated
independently, and therefore family history of cancer
information from these two families was not considered in
Table 2 Baseline characteristics of the participants in the study
Characteristic Number/mean (SD) Total Percentage/range
White Ethnicity (Northern European) 114 120 95.0%
Sex female 62 125 49.6%
Age at presentation (years) 49.0 (13.60) 124 18-86
<50 years 61 124 49%
≥50 years 63 124 51%
Currently smoking 21 87 24%
Ever smoking 51 88 58%
Colorectal cancer 49 119 41%
Proximal CRC 24 41 59%
Mean reported polyp number 39 (31.61) 116 5-150
Adenomas 98 115 85%
Advanced serrated polyps 47 70 67%
Family history of 1st degree relative with CRC 63 107 59%
Family history of first or second degree relative with CRC 66 91 73%
Int J Colorectal Dis (2010) 25:703–712 707this study. These two families have been described in detail
as case reports elsewhere [25].
Polyp number category
Seventy-three percent (n=66) had a reported number of
between five and 79 serrated polyps (moderate polyposis),
and the remainder had 80 or more (dense polyposis;
Table 5). Females were significantly under-represented in
the dense polyposis group (P=0.02). Family history of
CRC was inversely associated with polyp count category
with the dense polyposis group having significantly less
family history than those with moderate polyposis (P=
0.049). Though the rate of CRC did not differ between the
two groups, patients presenting with CRC in the dense
polyposis group were more likely to have a distal CRC. In
Table 3 Univariate analyses of phenotypic features and risk factors in 126 patients
Exposure Number/mean (SD) Total Percentage/range Significance (P value)
Age at presentation (years)
Females 49 (45.16) 62 19-86 0.98
Males 49 (45.76) 61 18-67
With CRC 51(46.50) 49 18-86 0.91
Without CRC 48 (44.89) 68 19-67
Colorectal cancer
Females 23 59 39% 0.58
Males 26 59 44%
CRC proximal 24 41 59%
Multiple proximal CRC 9 24 38% 0.04
Multiple distal CRC 0 18 0%
Female CRC—proximal 13 18 72% 0.12
Male CRC—proximal 11 23 48%
CRC Distal
<50 years of age 12 20 60% 0.02
≥50 years of age 4 19 22%
Mean reported polyp number 39 (31.61) 116 5-150
With CRC 47 (36.09) 43 5-150 0.13
Without CRC 35 (28.50) 68 5-150
Females 34 (27.76) 56 5-150 0.44
Males 44 (34.66) 59 5-150
Age group <50 years 45 (36.53) 55 5-150 0.03
≥50 years 34 (25.84) 59 5-129
With first degree relative with CRC 32 (25.65) 60 5-150 0.008
Without first degree relative with CRC 53 (41.29) 42 11-150
With any degree relative with CRC 36 (29.78) 64 5-150 0.003
Without any degree relative with CRC 58 (36.58) 25 11-129
Smoking
Current 51 (37.95) 21 5-129 0.43
Not currently smoking 34 (28.41) 66 5-150
Ever 41 (31.53) 52 5-129 0.56
Never 32 (30.52) 37 5-150
Adenomas
CRC 42 43 98% 0.03
Without CRC 54 67 81%
Advanced serrated polyps
CRC 19 28 68% 0.92
Without CRC 26 39 67%
Females 28 38 74% 0.44
Males 21 33 64%
<50 years of age 19 31 51% 0.31
≥50 years of age 27 37 73%
708 Int J Colorectal Dis (2010) 25:703–712contrast, proximal CRC predominated in the moderate
polyposis group. Patients who met WHO criterion 3 for
HPS (>30 hyperplastic polyps) were also significantly less
likely to have a family history of CRC (P=0.04), though no
male predominance was seen, nor were distal CRC more
common. Current smokers were more prevalent in the
higher polyp count categories for both classifications but
this was not statistically significant (P=0.39 and 0.44).
Multivariate analysis indicated that both the male predom-
inance and the lack of family history of CRC were
independent predictors of dense polyposis (Table 6).
Discussion
In this study, we examined the spectrum of phenotypic
features in a large group of patients with multiple serrated
polyps recruited from genetics clinics. Our results demon-
Moderate (5-79 polyps) Dense (80 polyps or more)
n=66 n=14
Mean (SD) Mean (SD) P value
Age (years) 48.2 (13.6) 44.5 (15.1) 0.36
a
N (%) N (%) OR (95% CI), P value
Gender
Female 34 (50%) 2 (14%) 6.0 (1.25-28.86),
Male 34 (50%) 12 (86%) 0.018
b
CRC
No 41 (64%) 6 (43%) 2.38 (0.73-7.7)
Yes 23 (36%) 8 (57%) 0.23
b
CRC Site
Proximal 13 (62%) 1 (17%) 8.13 (0.79-82.73)
Distal 8 (38%) 5 (83%) 0.077
b
First degree relative with CRC
No 27 (47%) 10 (77%) 0.26 (0.07-1.05)
Yes 31 (53%) 3 (23%) 0.066
b
First or second degree relative with CRC
No 16 (29%) 8 (62%) 0.25 (0.07-0.88)
Yes 40 (71%) 5 (38%) 0.049
b
Table 5 Univariate analysis of
risk variables for a moderate or
dense serrated polyp count in
the index cases
aIndependent samples t test for
comparison of age at presenta-
tion between moderate and
dense polyp groups
bP value from two-sided
Fisher’s exact test
Table 4 Comparison of case characteristics according to ascertainment (index vs. screening cases)
Variable Number (%) Index case P value Number (%) Screening case P value
Gender Male 49 (55) 13 (41)
Female 40 (45) NA 19 (59) 0.22
CRC Yes 37 (43) 09 (31)
No 48 (57) NA 20 (69) 0.28
FDR with CRC Yes 36 (48) 24 (88)
No 39 (52) NA 03 (12)
a 0.0002
b
Variable Mean (SD) Mean (SD)
Age 48 (14) NA 50 (12) 0.49
Mean polyp count 44 (34) NA 27 (21) 0.048
Mean polyp count Male 48 (36) 0.047 27 (20) 0.82
Mean polyp count Female 39 (30) 26 (22)
Mean polyp count FDR with CRC 34 (28) 0.026 26 (19) 0.49
Mean polyp count No FDR with CRC 55 (37) 43 (29)
aCases screened due to family history of colonic neoplasia (non-malignant, n=3)
bP value from two-sided Fisher’s exact test
Int J Colorectal Dis (2010) 25:703–712 709strate significant phenotypic heterogeneity and suggest that
both personal and familial risks of CRC in these patients
are associated with multiple factors.
Multiple serrated polyp patients demonstrated a high
level of CRC risk, with 41% of participants presenting with
CRC, a figure consistent with the findings of multiple
reports [9–11, 16, 17, 19, 20, 22]. In contrast, two reports
have suggested that HPS is not associated with an increased
risk of CRC [15, 21]. This may reflect variation in the
prevalences and exposures of genetic and environmental
risk factors, respectively, within these local populations.
Though polyp numbers were higher in patients with CRC
[12], neither polyp numbers, nor the presence of advanced
serrated polyps significantly determined whether a patient
presented with CRC. Consistent with a previous report
however, CRC was significantly associated with the
presence of adenomas [20]. Dysplasia in co-existing polyps
has also been reported previously as a risk factor for CRC
[17]. Adenomas are common in the general population
and it is likely that the factors which contribute to the
growth and development of serrated polyps in these
patients also act to increase the growth of a limited
number of micro-adenomas [26].
CRC arose in the proximal colon more often than would
be expected [27], with proximal cancers arising more
frequently in females. A high rate of multiple synchronous
CRCs was observed, with multiplicity significantly more
common in the proximal colon when compared to the distal
colon. In CRC arising via the serrated pathway, multiplicity
and proximal location have been previously reported as
associations [27, 28]. However, in patients less than
50 years, CRCs were more likely to be distal, which has
been reported recently as a feature of young-onset CRC in
general [29]. One of the largest HPS series reported to date
(38 patients with a mean age at presentation of 44 years)
found that 60% of CRC arose in distal sites [9]. This is an
important finding as the emphasis placed on the proximal
colon by the current WHO criteria may serve to distract
from the risk of CRC in the young onset patient with
multiple distal lesions whose presentation falls short of the
current criteria.
A slight male preponderance of 58% can be calculated
overall from the published reports on HPS [9–11, 13, 14,
16–22, 30], and notably the St. Mark’s study of 1980
suggested that HPS was a disorder of young males [21]. No
evidence of a male bias for multiple serrated polyps was
observed in our 126 patients, displaying an approximately
equal sex ratio when analysed overall. However, consider-
able differences were observed when this group of multiple
serrated polyp patients was stratified. The group with the
highest polyp numbers and the fewest relatives affected
with CRC was predominantly male, and this is consistent
with at least two previous reports, and may explain the
results of the St. Mark’s series of 1980 [21]. The question
arises as to whether these two results regarding gender and
family history of CRC might reflect ascertainment bias. It
could be postulated that individuals screened because of
CRC in a relative may be more likely to have a lower polyp
count because they are asymptomatic, and females may be
more likely to present for screening. However, relationships
between polyp count and both gender and family history of
CRC demonstrated this same pattern when only index cases
were examined. As would therefore be expected, asymp-
tomatic cases screened because of family history of colonic
neoplasia demonstrated lower polyp counts and a low rate
of CRC.
In this study, we found a significant increase in polyp
numbers associated with direct current exposure to cigarette
smoke, and suggests that rather than having a causal role in
HPS, smoke exposure may be associated with modulation
of phenotype, as manifested by increased polyp numbers.
This enhancement of phenotype was not unexpected as
population-based studies have consistently shown that the
association between smoking and colorectal cancer was
largely due to the strong effect of smoking on the subset of
CRC which arose through the serrated neoplasia pathway
[10, 31–33]. Smokers are more likely to present with
hyperplastic polyps, even in asymptomatic individuals [34],
with the most significant association between smokers and
serrated neoplasia in the population having both hyperplas-
tic and adenomatous polyps [35–37], a phenotype shared
with individuals with HPS. As has been demonstrated in
Table 6 Logistic regression analysis of putative predictors of a dense serrated polyp count in the index cases only
Dense polyp group (80-150 polyps) OR 95% Confidence interval P value
Lower Upper
Male gender 9.5 1.58 57.12 0.014
First degree relative with CRC 0.17 0.033 0.87 0.034
Occurrence of CRC 1.94 0.44 8.56 0.38
The moderate polyp group (5-79 polyps) was the reference group with age, ethnicity, and recruitment site included as co-variates in the final
analysis of main effects
710 Int J Colorectal Dis (2010) 25:703–712this report, multiple serrated polyps and CRC in a
background of multiple serrated polyps, both can occur in
the absence of smoking further supporting the premise that
smoking is likely to be a modifier of phenotype rather than
a causal factor. The two most significant predictors of
increased polyp number were male sex and lack of family
history of CRC, and this was independent of smoking
status.
A family history of CRC in first-degree relatives has
been reported in HPS by several authors [9–11, 19]. In our
study, patient recruitment was effected through high-risk
clinics, rather than through population-based screening, and
even though our findings for the rate of first-degree
relatives with CRC however are completely consistent with
an independent large series from the UK describing 32 HPS
patients [13], this method of recruitment is likely to have
inflated the risk of having affected relatives. Importantly,
40% of the patients in this study did not have a first-degree
relative with CRC, suggesting that patients with multiple
serrated polyps from genetics clinics are equally likely to be
referred in the absence of a first-degree family history of
CRC. Our current study demonstrated that family history of
CRC was relatively low in the group of patients with very
high polyp counts, thus highlighting the possibility of
genetic heterogeneity as a basis for the phenotypic variation
observed in this condition. Though this finding emerged
from a stratified analysis, separation of the predispositions
was incomplete; suggesting that predisposition to serrated
neoplasia may be a complex genetic condition.
In summary, our data support the notion, previously
proposed by multiple authors [6, 10, 30, 38, 39], that
patients with multiple serrated polyps have a heterogeneous
condition. The clinical importance in identifying HPS is
highlighted by the observation that 40% of HPS patients in
our cohort presented with CRC, frequently in the proximal
colon with an increased risk of multiplicity. Also of clinical
importance is the risk of CRC in relatives which is likely to
exceed that of the population, though quantitation of this
risk remains problematical [6, 39]. The study demonstrated
that young-onset patients with multiple serrated polyps are
more likely to develop a distal CRC despite the emphasis
placed on proximal disease by the WHO criteria. Impor-
tantly, the study has presented evidence for consideration
potentially highlighting heterogeneity in the mode of
inheritance of serrated polyp predisposition, with the
identification of a younger-onset group with highest polyp
counts, male gender and little family history of CRC,
features alluded to in an influential publication in 1980
[21]. The novel finding that family history varies inversely
with polyp count and gender, is unlikely to be confounded
by age, and is independent of ascertainment and smoking,
and suggests that patients with multiple serrated polyps
have a complex condition modified by a multitude of
genetic, environmental, and sex-specific factors. The
development of new clinical criteria with a biological basis
[13] to better define this predisposition and to identify those
with the highest personal and familial risks of CRC are
warranted.
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